<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MINOCYCLINE HYDROCHLORIDE</span><br/>(mi-noe-sye'kleen)<br/><span class="topboxtradename">Arestin, Dynacin, Minocin, </span><span class="topboxtradename">Myrac, </span><span class="topboxtradename">Vectrin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">tetracycline antibiotic</span><br/><b>Prototype: </b>Tetracycline<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 75 mg, 100 mg capsules; 50 mg, 75 mg, 100 mg tablets; 50 mg/5 mL suspension; 100 mg injection; 1 mg sustained release microspheres</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic tetracycline derivative which appears to be active against strains of <i>Staphylococci</i> resistant to other tetracyclines; photosensitivity occurs only rarely. Reported to be more completely absorbed than other
         <small>TETRACYCLINES</small> because it is more lipid-soluble.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against <i>Mycobacterium marinum</i> infections, <i>U. urealyticum,</i>
<i>N. gonorrhoeae</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of mucopurulent cervicitis, granuloma inguinale, lymphogranuloma venereum, proctitis, bronchitis, lower respiratory
         tract infections caused by <i>Mycoplasma pneumoniae,</i> Rickettsial infections, chlamydial infections, non-gonococcal urethritis, chlamydial conjunctivitis, plague, brucellosis,
         bartonellosis, tularemia, UTI, and prostatitis; <i>acne vulgaris,</i> gonorrhea, cholera, meningococcal carrier state,
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tetracyclines; oral administration in meningococcal infections; pregnancy (category D), lactation, children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal and hepatic impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Antiinfective</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 200 mg followed by 100 mg q12h<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span>
<i>&gt;8 y,</i> 4.4 mg/kg followed by 2 mg/kg q12h<br/><br/><span class="indicationtitle">Acne</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50 mg 13 times/d<br/><br/><span class="indicationtitle">Meningococcal Carrier State</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg q12h times 5 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;8 y,</i> 4 mg/kg followed by 2 mg/kg q12h times 5 d (max: 100 mg/dose)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Shake suspension well before administration.</li>
<li>Oral therapy is the preferred route; institute as soon as possible.</li>
<li>Check expiration date. Outdated tetracycline can cause severe adverse effects.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Reconstitute 100 mg with 5 mL of sterile water for injection; further dilute with 5001000 mL of D5W, NS, D5/NS, or RL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span> Start infusion immediately after preparation. Avoid rapid infusion. Give at a rate determined by the total volume of solution.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Doxapram, rifampin.</b>
<span class="incompattype">Y-site:</span>
<b>Allopurinol, amifostine, hydromorphone, meperidine, morphine, piperacillin/tazobactam, propofol, thiotepa, TPN.</b>
</p>
<ul>
<li>Reconstituted solution is stable at room temperature for 24 h; further diluted solution should be used immediately.</li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Weakness, light-headedness, ataxia, dizziness, or vertigo.</span>
<span class="typehead">GI:</span> Nausea, cramps, diarrhea, flatulence. <span class="typehead">Hepatic:</span> Hepatitis, liver enzyme increases, <span class="speceff-life">hepatotoxicity</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification"> antacids</span>, <b>iron,</b>
<b>calcium,</b>
<b>magnesium,</b>
<b>zinc,</b>
<b>kaolin and pectin,</b>
<b>sodium bicarbonate,</b>
<b>bismuth subsalicylate</b> can significantly decrease minocycline absorption; effects of both <b>desmopressin</b> and minocycline antagonized; increases <b>digoxin</b> absorption, increasing risk of <b>digoxin</b> toxicity; <b>methoxyflurane</b> increases risk of kidney failure. <span class="typehead">Food:</span> Dairy products significantly decrease minocycline absorption; food may also decrease its absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90100% absorbed from GI tract. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> Tends to accumulate in adipose tissue; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Partially metabolized. <span class="typehead">Elimination:</span> 2030% excreted in feces; about 12% excreted in urine. <span class="typehead">Half-Life:</span> 1126 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain history of hypersensitivity reactions prior to administration; drug is contraindicated with known tetracycline hypersensitivity.</li>
<li>Lab: C&amp;S should be drawn prior to initiation of therapy.</li>
<li>Monitor IV infusion site carefully, since thrombophlebitis occurs relatively often (see Appendix F).</li>
<li>Monitor carefully for signs of hypersensitivity response (see Appendix F), particularly in patients with history of allergies,
            especially to drugs.
         </li>
<li>Monitor at-risk patients for S&amp;S of superinfection (see Appendix F).</li>
<li>Assess risk of toxic effects carefully; increases with renal and hepatic impairment.</li>
<li>Determine serum drug level in patients receiving prolonged therapy.</li>
<li>Supervise ambulation, since lightheadedness, dizziness, and vertigo occur frequently.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid hazardous activities or those requiring alertness while taking minocycline.</li>
<li>Use sunscreen when outdoors and otherwise protect yourself from direct sunlight since photosensitivity reaction may occur.</li>
<li>Report vestibular adverse effects (e.g., dizziness), which usually occur during first week of therapy. Effects are reversible
            if drug is withdrawn.
         </li>
<li>Report loose stools or diarrhea or other signs of superinfection promptly to physician.</li>
<li>Use or add barrier contraceptive while they are taking drug if using hormonal contraceptive.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>